(Q82413482)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

title

Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

chronic lymphocytic leukemia

16 January 2020

main subject

1 reference

D E Spaner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

8 November 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

1144-1145

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22064354%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.329

16 January 2020

exact match

0 references

cites work

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021

High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021

Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021

Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021

Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.329

7 January 2021